This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Sarepta will share the panel’s recommendations with the U.S. Food & Drug Administration (FDA), and implementation of any new regimen will be subject to FDA guidance and allowance. In the ...

For a broader perspective on Sarepta’s outlook, explore how other analysts view the stock. Price Action: SRPT stock is trading lower by 9.96% to $17.09 at last check Wednesday.

FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector June 04, 2025 — 10:24 am EDT Written by RTTNews.com for RTTNews -> ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys ...

FDA evaluating further regulatory actions after deaths Elevidys is the only gene therapy for Duchenne muscular dystrophy Sarepta suggested updating Elevidys' label June 24 (Reuters) - The U.S ...

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported the death. FILE – The U.S. Food and Drug Administration campus in Silver Spring, Md., is photographed, Oct. 14 ...

Sarepta Therapeutics SRPT announced that the FDA has granted platform-technology designation to its viral vector rAAVrh74, used in the investigational gene therapy SRP-9003.

The rAAVrh74 viral vector is a key component in several of Sarepta’s gene therapy programs, including Elevidys, an already FDA-approved gene therapy for Duchenne muscular dystrophy. It is also ...